May 2nd 2024
Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.
ARVO 2023: Carl Danzig, MD, FASRS shares new data on vision loss from the GATHER clinical program
April 25th 2023Ophthalmology Times® spoke with Carl Danzig, MD, FASRS, at the 2023 ARVO annual meeting to learn more about the post hoc analysis for the GATHER trials and the new data on the correlation between vision loss and GA growth.
ARVO 2023: Apellis Pharmaceuticals presented Phase 3 data analyses of pegcetacoplan injection for GA
April 24th 2023Apellis Pharmaceuticals Inc. delivered an oral presentation at the ARVO Annual Meeting in New Orleans announcing their post hoc analyses from the Phase 3 OAKS and DERBY studies evaluating pegcetacoplan injection (Syfovre) for the treatment of geographic atrophy (GA).